http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110461850-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-147 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4375 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-147 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
| filingDate | 2018-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-10-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-10-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110461850-B |
| titleOfInvention | Fourth-generation EGFR tyrosine kinase inhibitor |
| abstract | The present invention provides a compound which has specific tyrosine kinase inhibitory activity against C797S mutant drug-resistant EGFR (especially C797S mutant three-drug-resistant EGFR), and is used as C797S mutant drug-resistant EGFR (especially C797S mutant drug-resistant EGFR). It is useful as a preventive or/or therapeutic agent and the like for a C797S mutant triple-resistant EGFR)-specific tyrosine kinase inhibitor, a non-small cell lung cancer having a drug-resistant mutant EGFR, or the like. The compound is a compound represented by formula (I) or a salt thereof, wherein X represents O or NH, R 1 and R 2 each independently represent a hydrogen atom or an optionally substituted hydrocarbon group, and R 3 and R 4 each independently independently represent a hydrogen atom, a halogen atom or an optionally substituted hydrocarbon group, R 5 and R 6 each independently represent an optionally substituted hydrocarbon group, and the compound represented by the formula (I) does not include the following compounds. |
| priorityDate | 2017-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 172.